(Press-News.org) A proven and effective medication for osteoporosis, which is currently only available as an injection, can be administered orally using a novel “robotic pill,” according to a study presented Saturday at ENDO 2023, the Endocrine Society’s annual meeting in Chicago, Ill.
“We believe this study provides the first clinical evidence of safe and successful delivery of the osteoporosis drug teriparatide through an oral robotic pill,” said Arvinder Dhalla, Ph.D., who leads Clinical Development at Rani Therapeutics, the San Jose, Calif.-based company that developed the technology and funded the study. “Data from this study are very encouraging and should give hope to those suffering from chronic conditions that require painful injections, like osteoporosis, that an oral alternative could be on the way.”
When a person swallows the robotic pill, it moves through the stomach intact. In the intestine the pill releases a self-inflating balloon with a microsyringe, which injects a drug-filled microneedle and delivers the medication.
“The intestines do not have pain response to needles, so the injection is painless,” Dhalla said. The needle rapidly dissolves, and the medication is absorbed while the delivery mechanism deflates and is safely passed out of the body.
“The robotic pill, which is essentially a swallowable auto-injector in the form of a pill, is designed to deliver the drug safely and efficiently as a painless intestinal injection,” she said.
The Phase I study of 39 healthy women evaluated the safety, tolerability and movement through the body of the robotic pill known as RT-102, containing a dose of the drug teriparatide (PTH 1-34). Teriparatide is a synthetic form of the natural human parathyroid hormone. It has been in clinical use for decades as an injectable medication (under the brand name Forteo®) for rebuilding brittle bones of osteoporosis patients. It is taken as a daily injection for up to two years.
Study participants were divided into three groups. Two groups received either a lower or higher dose delivered with the robotic pill, and the third group received a standard injection of teriparatide. Fluoroscopic imaging was used to track the robotic pill through and out the body. Drug concentrations were measured in blood samples collected over six hours. The study found the bioavailability (the ability of the drug to be absorbed and used by the body) of the drug delivered by the robotic pill was comparable to or better than the drug given via the injection.
“This breakthrough technology of converting injections into oral pills is a significant step forward towards ending the burden of painful injections for millions of patients suffering from chronic diseases,” Dhalla said.
Dhalla is scheduled to present at the Society’s ENDO 2023 hormones and technology news conference at 9 AM Central on Saturday, June 17. Register to view the news conference livestream at endomediastream.com.
# # #
Endocrinologists are at the core of solving the most pressing health problems of our time, from diabetes and obesity to infertility, bone health, and hormone-related cancers. The Endocrine Society is the world’s oldest and largest organization of scientists devoted to hormone research and physicians who care for people with hormone-related conditions.
The Society has more than 18,000 members, including scientists, physicians, educators, nurses and students in 122 countries. To learn more about the Society and the field of endocrinology, visit our site at www.endocrine.org. Follow us on Twitter at @TheEndoSociety and @EndoMedia.
END
Study finds “robotic pill” can safely deliver injectable osteoporosis drug
2023-06-17
ELSE PRESS RELEASES FROM THIS DATE:
Wider search needed to improve outcomes for eosinophilic food allergy
2023-06-17
The good news: a monoclonal antibody treatment called benralizumab proved quite effective in a clinical trial at depleting the number of eosinophils found in the blood and digestive tract tissues of patients with eosinophilic gastritis.
The not-so-good news: eliminating eosinophils was not enough to stop the symptoms people feel with this uncommon and severe form of food allergy. Nor did the treatment affect key measures of gut tissue health and related gene expression patterns.
These paradigm-shifting Phase 2 clinical ...
University of Montana science unlocks secrets of high-elevation pregnancies
2023-06-17
MISSOULA – Pregnancy at high elevations often is associated with low birth weights and other complications. These challenges occur in a wide range of mammals, from deer mice to human beings.
Research conducted at the University of Montana revealed some of the genetic underpinnings that allow certain highland mouse populations to protect developing fetuses in higher areas. The work was published recently in the Proceedings of the National Academy of Sciences.
“Understanding how deer mice survive and thrive at high elevations not only informs our understanding of basic evolutionary processes, it may also one ...
ASU study: Jupiter’s moon Europa may have had a slow evolution
2023-06-16
Jupiter's moon, Europa, is slightly smaller than Earth’s Moon and is one of the most promising places to search for alien life.
Amid the Jovian system, Europa is of particular interest to scientists because of the strong evidence for nutrients, water and energy to potentially provide a habitable environment for some form of life beyond Earth. In addition, Europa is believed to be made up into four layers (from surface to center): an ice shell, salt water ocean, rocky mantle, and metallic core.
Like Earth, Europa’s ...
Adagrasib effective for patients with KRAS G12C-mutant lung cancer and untreated brain metastases
2023-06-16
HOUSTON ― Researchers from The University of Texas MD Anderson Cancer Center found the KRAS G12C inhibitor adagrasib showed promising activity suppressing cancer growth not only within the lungs but also in brain metastases for patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC).
Findings from the Phase Ib cohort of the KRYSTAL-1 trial, published today in the Journal of Clinical Oncology, represent the first prospective data of anti-tumor activity from a KRAS G12C inhibitor in brain metastases, providing continued evidence of the ...
ACQUIRE therapy framework shows results for intensive pediatric rehabilitation
2023-06-16
Virginia Tech researchers with the Fralin Biomedical Research Institute at VTC have demonstrated that children with a wide range of diagnoses that affect their motor function improve after receiving intensive pediatric neurorehabilitation called ACQUIRE Therapy.
The findings were published in June in Behavioral Sciences and will be included in an upcoming special issue of the journal devoted to “shifting the therapeutic paradigm for children with neuromotor disabilities to maximize development.”
“We ...
New research shows HIV can lie dormant in the brain
2023-06-16
As a part of its life cycle, the human immunodeficiency virus-1 (HIV) inserts a copy of its DNA into human immune cells. Some of these newly infected immune cells can then transition into a dormant, latent state for a long period of time, which is referred to as HIV latency.
Although current therapies, such current antiretroviral therapy (ART), can successfully block the virus from replicating further, it cannot eradicate latent HIV. If treatment is ever discontinued, the virus can rebound from latency and reignite the progression of HIV infection to AIDS.
Scientists from the HIV Cure Center at the UNC School of Medicine, University of California ...
For resistant breast cancers, two drugs may be better than one
2023-06-16
Cancer cells are even smarter than scientists previously believed, according to new CU Boulder research. When these cells are confronted with potent new drugs called CDK2 inhibitors, which are designed to prevent cancer from proliferating, they can trigger a workaround to survive the assault in as little as one to two hours.
But the study, published June 8 in the journal “Cell,” comes with a silver lining.
It reveals how cancer cells complete this adaption and shows that simultaneously administering a second, already widely ...
UMass Amherst biostatistician developing statistical tools to predict breast cancer survival and inform targeted therapies
2023-06-16
Breast cancer is a complex disease, and its progression is difficult, yet important, to predict.
While many elements may contribute to a breast cancer prognosis, University of Massachusetts Amherst biostatistician Chi Hyun Lee has zeroed in on one risk factor that has emerged for its potential to predict the disease’s progression.
Lee will use a two-year, $154,791 grant from the National Institutes of Health (NIH) in an effort to develop statistical tools that will better predict breast cancer survival rates and survival time after breast cancer recurrence.
While the project focuses on breast cancer research, the proposed statistical ...
Jefferson Lab outreach efforts earn national recognition
2023-06-16
NEWPORT NEWS, VA – When the global pandemic put the kibosh on in-person events, the U.S. Department of Energy’s Thomas Jefferson National Accelerator Facility sought alternatives for ensuring its world-class science and unique equipment remained accessible. These efforts culminated in the Fall for Science Virtual Field Trip Event, which rolled out a virtual tour experience, new website, and unique supporting materials. Now, the event has been recognized by the Public Relations Society of America with three Anvil Awards.
According ...
Uncovering a cellular process that leads to inflammation
2023-06-16
Cedars-Sinai investigators have identified several steps in a cellular process responsible for triggering one of the body’s important inflammatory responses. Their findings, published in the peer-reviewed journal Science Immunology, open up possibilities for modulating the type of inflammation associated with several infections and inflammatory diseases.
Specifically, the investigators have improved understanding of the steps that lead to the production of IL-1 beta, a potent inflammatory protein signal released during many inflammatory responses.
“We now have a clearer understanding of the stepwise process that leads to the production of IL-1 beta,” said Andrea ...